摘要
目的：对树突状细胞（DC）和细胞因子诱导的杀伤细胞（CIK）联合化疗治疗晚期非小细胞肺癌（NSCLC）的相关文献进行Meta分析,了解生物免疫治疗联合化疗治疗晚期NSCLC的临床疗效。方法：检索中文期刊数据库、维普数据库、万方数据库及Pub Med、CBM等西文数据库,查找DC-CIK或CIK联合化疗治疗NSCLC的临床研究文献。采用Jadad评分量表对纳入文献进行质量评价,使用Revman 4.2统计软件对临床疗效、生活质量及免疫检测指标（CD3^＋、CD4^＋、CD4^＋/CD8^＋）进行Meta分析。结果：经筛选后纳入11篇随机对照临床试验文献,质量分析显示纳入文献质量不高。临床获益合并效应比值比（OR）为2.45,95%CI为1.56-3.83;生活质量合并效应量OR为3.17,95%CI为1.82-5.52;治疗后免疫学检测指标CD3＋的合并效应量OR为16.96,95%CI为14.09-17.82;CD4^＋的合并效应量OR为6.84,95%CI为6.06-8.63;CD4^＋/CD8^＋的合并效应量OR为0.60,95%CI为0.56-0.65。DC-CIK或CIK联合化疗治疗NSCLC的临床获益率及生活质量明显优于对照组,治疗后免疫功能也优于对照组。结论：DC-CIK或CIK能明显提高晚期NSCLC患者的临床获益率及生活质量,并能提高化疗后患者免疫功能。
Objective： To study the clinical efficacy of biological immune therapy of dendritic cell（ DC） or cytokine-induced killers cell（ CIK） combined with chemotherapy in the treatment of advanced non-small cell lung cancer（ NSCLC） by using Meta-analysis and systematic review of the literature. Methods： Randomized controlled trials（ RCT） papers were searched in China Academic Journals,China National Knowledge Infrastructure,Wei Pu and Wanfang database,Pub Med and CBM foreign database. Jadad scale was used to devalue the quality of the included papers; Meta-analysis of the clinical efficacy,the life quality and the immunologic function（ CD3^＋、CD4^＋、CD4^＋/ CD8^＋） was performed with Revman 4. 2 software. Results： Eleven RCT papers were included after screening,and the quality of the papers obtained low Jadad score. Meta-analysis showed that the odds ratio（ OR） of the combined clinical benefit rate was2. 45,95% CI 1. 56 to 3. 83; the OR of the life quality was 3. 17,95% CI 1. 82 to 5. 52. After treatment,the levels of CD3^＋in the immunotherapy group increased to 16. 96,95% CI 14. 09 to 17. 82,the levels of CD4＋increased to 6. 84,95% CI 6. 06 to 8. 63 and the levels of CD4^＋/ CD8^＋increased to 0. 60,95% CI 0. 56 to 0. 65. The clinical benefit rate and the immunologic function rate of the DC-CIK therapy or CIK combined with chemotherapy were superior to those of the control in the treatment of NSCLC. Conclusions：Biological immune therapy of DC-CIK or CIK combined with chemotherapy can help to improve the clinical benefit rate,the life quality and immunologic function of the patients with advanced NSCLC.
出处
《蚌埠医学院学报》
CAS
2014年第11期1508-1511,1514,共5页
Journal of Bengbu Medical College
关键词
癌
非小细胞肺
生物免疫治疗
树突状细胞
杀伤细胞
carcinoma
non-small cell lung
biological immune therapy
dendritic cell
killers cell
